Promising Immunotherapies against COVID-19

被引:4
|
作者
Guo, Haodong [1 ]
Zhou, Lili [1 ]
Ma, Zhenyu [1 ]
Tian, Zhixin [1 ]
Zhou, Fangfang [1 ]
机构
[1] Soochow Univ, Inst Biol & Med Sci, Jiangsu Key Lab Infect & Immun, Suzhou 215123, Jiangsu, Peoples R China
基金
中国国家自然科学基金; 美国国家科学基金会;
关键词
convalescent plasma; coronavirus disease 2019; COVID-19; cytokine storm; immunotherapy; interferon; severe acute respiratory syndrome coronavirus 2; RESPIRATORY SYNDROME CORONAVIRUS; CYTOKINE STORM; III INTERFERONS; VACCINE; PROTEIN; SPIKE; RIBAVIRIN; RESPONSES; EFFICACY; EVASION;
D O I
10.1002/adtp.202100044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a severe pandemic and deeply affected the livelihood of people worldwide. In response to the pandemic, researchers have been rapidly studying different aspects of COVID-19, such as virus detection, vaccinations, and epidemiological aspects of the disease. It has been reported that SARS-CoV-2 can induce uncontrolled inflammation and cause a lack of antiviral response, thereby aggravating the disease. Therefore, recovery of immune functions is key to COVID-19 treatment. Many clinical trials are exploring suitable therapies, and some progress has been made. Early administration of interferons may prevent COVID-19 exacerbation and/or promotes recovery from the diseases. Inhibitors of inflammation can prevent cytokine storms and multi-organ damage. Convalescent plasma containing neutralizing antibodies has played an important role in therapeutic options at the beginning of the pandemic owing to the lack of other effective methods. To aid the development of treatment options for COVID-19, this review focuses on immunotherapies, including treatment with interferons, inhibition of pro-inflammatory mechanisms, and the use of convalescent plasma.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] A promising vaccine candidate against COVID-19
    Wang, Xiwei
    Tu, Wenwei
    MOLECULAR BIOMEDICINE, 2020, 1 (01):
  • [2] A promising vaccine candidate against COVID-19
    Xiwei Wang
    Wenwei Tu
    Molecular Biomedicine, 1
  • [3] Flavonoids are promising safe therapy against COVID-19
    Alzaabi, Moza Mohamed
    Hamdy, Rania
    Ashmawy, Naglaa S.
    Hamoda, Alshaimaa M.
    Alkhayat, Fatemah
    Khademi, Neda Naser
    Al Joud, Sara Mahmoud Abo
    El-Keblawy, Ali A.
    Soliman, Sameh S. M.
    PHYTOCHEMISTRY REVIEWS, 2022, 21 (01) : 291 - 312
  • [4] Cinnamon: A Promising Natural Product Against COVID-19
    Zareie, Azadeh
    Soleimani, Davood
    Askari, Gholamreza
    Jamialahmadi, Tannaz
    Guest, Paul C.
    Bagherniya, Mohammad
    Sahebkar, Amirhossein
    IDENTIFCATION OF BIOMARKERS, NEW TREATMENTS, AND VACCINES FOR COVID-19, 2021, 1327 : 191 - 195
  • [5] Promising Enzymes for Inhibitors Development Against COVID-19
    Sun, Zhi-Gang
    Yu, Feng-Ling
    Qiu, Xiang-Ting
    Li, Shuang
    Li, Xue-Tang
    Zhu, Hai-Liang
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2022, 22 (03) : 449 - 456
  • [6] Flavonoids are promising safe therapy against COVID-19
    Moza Mohamed Alzaabi
    Rania Hamdy
    Naglaa S. Ashmawy
    Alshaimaa M. Hamoda
    Fatemah Alkhayat
    Neda Naser Khademi
    Sara Mahmoud Abo Al Joud
    Ali A. El-Keblawy
    Sameh S. M. Soliman
    Phytochemistry Reviews, 2022, 21 : 291 - 312
  • [7] Surrogate cytokine agonists: promising agents against COVID-19
    Lin, Zemin
    Zuo, Jianping
    He, Shijun
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [8] Tocilizumab as a promising agent against COVID-19: Issues and challenges
    Dastan, Farzaneh
    Tabarsi, Payam
    Abedini, Atefeh
    Saffaei, Ali
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2021, 26 (01):
  • [9] Advance of promising targets and agents against COVID-19 in China
    Duan, Yongtao
    Zhu, Hai-Liang
    Zhou, Chongchen
    DRUG DISCOVERY TODAY, 2020, 25 (05) : 810 - 812
  • [10] Surrogate cytokine agonists: promising agents against COVID-19
    Zemin Lin
    Jianping Zuo
    Shijun He
    Signal Transduction and Targeted Therapy, 7